The FDA Peptide Panel: Could These 7 Be Compounded?
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
An FDA advisory panel meets July 23 and 24 to weigh whether seven peptides should be added to the list of ingredients that licensed pharmacies are allowed to compound (FDA). The panel's vote is a recommendation, not a final rule, and the FDA's own reviewers have suggested not adding any of the seven (Drug Topics).
Who This Helps
This is for anyone following the peptide space, anyone who has seen these ingredients sold online, and anyone trying to understand what is and is not allowed. It is also for people who take a compounded GLP-1 and want to know whether this affects them.
What Is Happening July 23 and 24
The FDA's Pharmacy Compounding Advisory Committee is meeting to review seven peptides for possible inclusion on the 503A Bulks List, which is the set of bulk ingredients that licensed 503A pharmacies may use in compounding (FDA). Getting on that list is the gateway that would let a licensed pharmacy compound one of these peptides for a patient.
Which Seven Peptides Are Under Review
None of these are GLP-1 weight-loss drugs. They are peptides often sold in wellness and research circles, and the committee is reviewing them over the two days (FDA):
- Day one: BPC-157, KPV, TB-500, and MOTS-C.
- Day two: Emideltide (also called DSIP), Semax, and Epitalon.
What the FDA's Reviewers Recommend
The FDA's briefing documents propose the same answer for all seven: do not add them to the list, largely because the agency wants more evidence on safety and quality (RAPS). The committee can agree or disagree, but its role is advisory, so the FDA makes the final call afterward and is not bound by the vote.
What It Could Mean for Compounding
If the FDA ultimately adds a peptide to the 503A Bulks List, a licensed pharmacy could compound it for patients with a prescription, which is how compounding works for approved bulk ingredients (FDA). Until a peptide is actually added, it is not cleared for compounding, and this panel by itself does not legalize anything. For the difference between pharmacy types, see our explainer on 503A and 503B pharmacies.
This Is Not About Your GLP-1
It is easy to mix these up, so it is worth being clear. These seven are wellness and research peptides, not the GLP-1 medicines used for weight loss, and they travel a separate regulatory path from semaglutide and tirzepatide products (National Law Review). Whatever the panel recommends, it does not change how your GLP-1 is prescribed or compounded. For background on the wider shift, see our post on the 2026 FDA peptide reclassification.
What to Watch and How to Stay Safe
Whatever happens at the meeting, be cautious about how these peptides are sold. Be wary of sellers who market them as FDA approved or claim they are the same as a licensed pharmacy's product, and stick to licensed 503A or 503B pharmacies rather than grey-market sites (FDA).
What this means for you: follow the outcome, but do not act on hype from a sales page. You can compare providers, including compounding options and the pharmacies they work with, using the GLP Winner provider survey, and read more on grey-market peptides.
Final Takeaway
An FDA panel is reviewing seven peptides this week, and the agency's reviewers are leaning against adding them for now. The vote is a recommendation, not the last word.
If a peptide eventually lands on the 503A list, licensed pharmacies could compound it. Until then, it is not cleared, and this meeting alone changes nothing on the shelf.
None of this touches your GLP-1, which follows a separate path. That is the key point to hold onto amid the noise.
The safest move is patience and good sourcing. Watch the outcome, and keep to licensed pharmacies rather than grey-market sellers.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
What is the FDA peptide panel meeting about?
The FDA's Pharmacy Compounding Advisory Committee meets July 23 and 24, 2026 to review seven peptides for the 503A Bulks List. That list determines which bulk ingredients licensed pharmacies may use in compounding.
Which peptides are being reviewed?
The seven are BPC-157, KPV, TB-500, MOTS-C, Emideltide (DSIP), Semax, and Epitalon. None of them are GLP-1 weight-loss medications.
Will this panel make peptides legal to compound?
Not by itself. The committee only makes a recommendation, and the FDA decides later. A peptide is cleared for compounding only if the FDA actually adds it to the 503A Bulks List, and the agency's reviewers have suggested not adding these seven.
Does this affect my GLP-1 medication?
No. These seven are wellness and research peptides that follow a separate path from GLP-1 drugs like semaglutide and tirzepatide. The panel's outcome does not change how your GLP-1 is prescribed or compounded.
Are these peptides safe to buy online right now?
The FDA has not approved these peptides, and its reviewers want more safety and quality evidence. Be cautious of grey-market sellers, and stick to licensed 503A or 503B pharmacies rather than sites that market them as approved.
Sources
Keep Reading
Some peptides are FDA-approved medicines and some "research" peptides are risky. A plain-language guide to telling safe sources from unsafe ones.
Lab testing finds many grey-market peptides miss their purity claims, with heavy metals and bacterial contamination in samples. Here is what to know.
The FDA removed 12 peptides from a restricted category in April 2026. What that means for access, safety, and your GLP-1 care.
Categories
Curated by
